Skip to main content

Table 4 Biomarker at baseline and day seven as predictor for days with restricted activities or persistence of discomfort after 14 days

From: Infection biomarkers in primary care patients with acute respiratory tract infections–comparison of Procalcitonin and C-reactive protein

Days with restricted activites: coefficient (95 % CI)

 

Demographic-adjusted model

Fully adjusted model a

Demographic-adjusted model

Adjusted a

Biomarker at baseline

CRP (mg/dL)

0.4 (−0.2 to 0.9), p = 0.169

0.3 (−0.3 to 0.9), p = 0.324

Biomarker on day 7

0.7 (0.1 to 1.4), p = 0.035

0.6 (−0.1 to 1.3), p = 0.075

CRP ≤20

Reference group

Reference group

Reference group

Reference group

CRP 20-50

0.4 (−0.5 to 1.3), p = 0.37

0.4 (−0.5 to 1.3), p = 0.407

0.7 (−0.6 to 2.0), p = 0.264

0.8 (−0.5 to 2.1), p = 0.252

CRP 50-100

0.0 (−1.0 to 1.0), p = 0.956

−0.1 (−1.0 to 0.9), p = 0.920

2.5 (0.3 to 4.7), p = 0.024

2.4 (0.2 to 4.5), p = 0.035

CRP >100

1.6 (0.5 to 2.6), p = 0.005

1.4 (0.3 to 2.5), p = 0.014

3.3 (0.5 to 6.2), p = 0.022

2.7 (−0.3 to 5.7), p = 0.078

PCT (μg/L)

0.9 (0 to 1.9), p = 0.048

0.8 (−0.2 to 1.8), p = 0.123

0.7 (−0.6 to 2.1), p = 0.297

0.5 (−0.9 to 1.9), p = 0.484

PCT ≤0.1

Reference group

Reference group

Reference group

Reference group

PCT 0.1-0.25

0.4 (−0.4 to 1.2), p = 0.320

0.3 (−0.5 to 1.1), p = 0.407

0.6 (−0.4 to 1.6), p = 0.249

0.5 (−0.5 to 1.5), p = 0.353

PCT 0.25-0.5

1.6 (−1.3 to 4.4), p = 0.288

1.2 (−1.8 to 4.1), p = 0.434

2.9 (−1.5 to 7.3), p = 0.194

2.3 (−2.1 to 6.7), p = 0.300

PCT >0.5

2.0 (0.0 to 4.0), p = 0.045

1.8 (−0.3 to 3.8), p = 0.089

−0.3 (−4.6 to 4.1), p = 0.900

−0.7 (−5.1 to 3.7), p = 0.751

Persistence of discomfort after 14 days: coefficient (95 % CI)

 

Demographic-adjusted model

Adjusted a

Demographic-adjusted model

Adjusted a

Biomarker at baseline

CRP (mg/dL)

1.0 (0.8 to 1.4), p = 0.831

1.0 (0.8 to 1.4), p = 0.828

Biomarker on day 7

1.7 (1.2 to 2.4), p = 0.005

1.7 (1.2 to 2.5), p = 0.005

CRP ≤20

Reference group

Reference group

Reference group

Reference group

CRP 20-50

1.2 (0.7 to 1.9), p = 0.517

1.2 (0.7 to 2), p = 0.436

1.6 (0.8 to 3.2), p = 0.203

1.7 (0.8 to 3.4), p = 0.166

CRP 50-100

1.0 (0.6 to 1.8), p = 0.862

1.1 (0.6 to 1.8), p = 0.828

3.4 (0.9 to 13.1), p = 0.078

3.4 (0.8 to 13.5), p = 0.085

CRP >100

1.2 (0.7 to 2.2), p = 0.477

1.2 (0.7 to 2.3), p = 0.514

6.4 (0.7 to 54.8), p = 0.091

4.5 (0.5 to 40.9), p = 0.18

PCT (μg/L)

1.1 (0.6 to 1.7), p = 0.845

1.0 (0.6 to 1.7), p = 0.939

0.9 (0.4 to 1.9), p = 0.804

0.8 (0.4 to 1.7), p = 0.588

PCT ≤0.1

Reference group

Reference group

Reference group

Reference group

PCT 0.1-0.25

0.8 (0.5 to 1.3), p = 0.439

0.8 (0.5 to 1.3), p = 0.466

1.1 (0.7 to 1.9), p = 0.655

1.1 (0.6 to 1.9), p = 0.738

PCT 0.25-0.5

3.3 (0.6 to 18.0), p = 0.166

2.9 (0.5 to 16.3), p = 0.229

2.5 (0.2 to 28.5), p = 0.460

1.8 (0.2 to 21.4), p = 0.63

PCT >0.5

1.6 (0.5 to 4.7), p = 0.402

1.5 (0.5 to 4.5), p = 0.486

0.5 (0.0 to 5.7), p = 0.540

0.3 (0.0 to 4.6), p = 0.42

  1. Adjusted for: gender, comorbidities, years of education, randomization (aadditional adjustment: prescription of antibiotics, days with RA prior to randomization)